The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
about
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesRegional therapies for in-transit diseaseSynthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal.CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.Tim-3 expression defines regulatory T cells in human tumors.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumoursEfficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route.Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology.Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment.Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunitDynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancerAdoptive T-cell transfer in melanoma.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.Isolated limb infusion as a model to test new agents to treat metastatic melanoma.CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo.Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer.Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities.
P2860
Q26799357-EF219CBB-3983-40C5-93CA-D13E95FDAC55Q26991991-A888CBE0-AF33-4F7B-AB85-AED8132124E6Q28087553-D1A18EF7-0A10-49B2-9502-634229CA9818Q30577136-8124FCB2-BFE2-41FE-B77D-E1A56F17E9A7Q34323663-15BF6945-8616-4EEC-B066-02D934110849Q34634058-618DD446-F01D-4300-9C20-DABB2646985BQ34744875-526BFC6F-CF3D-4CB1-A723-A6F3FB3D6FB6Q35224721-EBB0EF42-3709-46D6-A18A-67BACFA2D7EEQ35440744-239D21A3-CEF3-4C86-A457-C5D4E7653C39Q35507024-B75B11A2-1D70-42C9-81E6-6BEA22F5B9C3Q36544143-39B0DD59-3E3D-4C77-8C36-5CFD6F93BB7DQ36716083-53DE937A-21BC-41F1-AB87-6447A902E90BQ36821243-1B2A4872-AD73-4F00-8DB3-F8F64B04E46FQ36863278-E4980B06-4BDD-44D6-B98D-C365DA759644Q37111149-B13AF86F-0C83-4CB0-8ED6-490E80131323Q37225501-EF089764-87C7-435E-AE13-5CEE2F237C50Q38068968-5F659A32-C89B-44C5-A85A-371BFCFF4ADCQ38089937-BD7F60AB-0143-44B4-A9DE-9F095F56DAD7Q38187595-57EEF33E-057A-421F-91DB-F844ADEFD163Q38753870-AB87F275-B3EC-4B7E-BEAD-3702C0151477Q41098451-177CBC76-959F-456A-8523-68E12A07B41AQ42783139-750C74E2-88C9-49D3-B649-7BB4785E92DEQ47140960-AE011209-1A5D-48C5-808C-B1C418AAE07FQ48206682-1A4136F0-B3A1-4FA8-8AB2-543FB2DFFF01
P2860
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@ast
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@en
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@nl
type
label
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@ast
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@en
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@nl
prefLabel
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@ast
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@en
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@nl
P3181
P1433
P1476
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
@en
P2093
J.-P. Abastado
P304
P3181
P356
10.1158/0008-5472.CAN-11-3538
P407
P577
2012-05-01T00:00:00Z